| Typicality: | 0.109 |
| Saliency: | 0.051 |
| in hct recipients | 4 | transitive-object |
| currently | 2 | temporal |
| therapy → be approved for → the prevention of cmv | 4 |
| negative | neutral | positive |
| 0.305 | 0.601 | 0.095 |
| Raw frequency | 4 |
| Normalized frequency | 0.051 |
| Modifier score | 0.000 |
| Perplexity | 46.225 |